Fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema

Wyatt B. Messenger, Robert M. Beardsley, Christina J. Flaxel

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations


Diabetic macular edema (DME) remains one of the leading causes of moderate to severe vision loss. Although laser photocoagulation was the standard of care for several years, few patients achieved significant improvements in visual acuity. As a result, several pharmacotherapies and surgeries have been investigated. The fuocinolone acetonide devices are one of the latest therapies considered for the treatment of DME. Despite bringing significant improvements in visual acuity, fuocinolone devices are associated with cataract formation, increased intraocular pressure (IOP), and surgery to lower IOP. Due to the risk of complications, fuocinolone acetonide devices should be considered only in cases refractive to first-line therapies. In this review, we evaluate current and emerging therapies for DME, with special emphasis on fuocinolone acetonide intravitreal devices.

Original languageEnglish (US)
Pages (from-to)425-434
Number of pages10
JournalDrug Design, Development and Therapy
StatePublished - May 23 2013
Externally publishedYes


  • Anti-VEGF
  • Dexamethasone
  • Diabetic macular edema
  • Fuocinolone
  • Triamcinolone


Dive into the research topics of 'Fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema'. Together they form a unique fingerprint.

Cite this